Bbv-152 antigen adjuvated with algel-imdg
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- Bbv-152 antigen adjuvated with algel-imdg
- bbv 152 antigen adjuvated with algel imdg
- Bbv-152 antigen adjuvated with algel-imdg
- covaxin
- Covaxin
- COVAXIN
- covaxin bbv152
- ChEMBL ID
- CHEMBL4802199
- FDA ingredient codes (UNII)
- 76QBM68XR2
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
Open Targets indications
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT04918797
- NCT05522335
- NCT05567471
- NCT05639998
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (5)
- BBV152/BBV154 Heterologus Prime-Boost Study
- COVAXIN in a Pediatric Cohort
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
- Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose
- Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers
In development for (1)
- COVID-19 Phase 3